Comprehensive Treatment of An Advanced Lung Cancer Patient with
EGFR Driver Gene Positive.
10.3779/j.issn.1009-3419.2021.101.20
- Author:
Shuai WANG
1
;
Xianjun MIN
1
;
Yingshun YANG
1
;
Guotian PEI
1
;
Qiang LIU
1
;
Jun LIU
1
;
Yuqing HUANG
1
Author Information
1. Department of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital),
Beijing 100080, China.
- Publication Type:Journal Article
- Keywords:
Adverse reaction;
Eepidermal growth factor receptor-tyrosine kinase inhibitor;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2021;24(6):447-452
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most common malignant tumor and the leading cause of cancer-related death worldwide. Most of the patients have distant metastasis when visiting the doctor, which seriously affects the survival time and quality of life of the patients. With the development of molecular targeted drugs, lung cancer treatment has been transformed from traditional chemotherapy to targeted therapy and precision medicine has been gradually applied in clinical practice, which can make lung cancer patients live longer and have a better quality of life. We present a case of advanced lung cancer patient who presented to Department of Thoracic Surgery of Beijing Haidian Hospital five years ago. We chose the reasonable treatment options though the genetic tests and circulating tumor DNA tests. We summarized the adverse reactions in the whole course of treatment. The comprehensive therapy we utilized, including targeted therapy, chemotherapy, antiangiogenic agents and local radiotherapy, have resulted in our patient with remaining alive. For advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutation positive, individualized treatment was conducted based on precise genotyping and dynamic monitoring, which can not only control the tumor, but also have mild toxic and side effects. The survival time of the patients was prolonged and the quality of life was guaranteed.
.
